DE69928814D1 - Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten - Google Patents
Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheitenInfo
- Publication number
- DE69928814D1 DE69928814D1 DE69928814T DE69928814T DE69928814D1 DE 69928814 D1 DE69928814 D1 DE 69928814D1 DE 69928814 T DE69928814 T DE 69928814T DE 69928814 T DE69928814 T DE 69928814T DE 69928814 D1 DE69928814 D1 DE 69928814D1
- Authority
- DE
- Germany
- Prior art keywords
- tgf
- treatment
- beta inhibitors
- cerebral diseases
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98116692 | 1998-09-03 | ||
| EP98116692 | 1998-09-03 | ||
| EP99104033 | 1999-03-16 | ||
| EP99104033 | 1999-03-16 | ||
| PCT/EP1999/006433 WO2000013705A1 (en) | 1998-09-03 | 1999-09-01 | Use of tgf-beta inhibitors for treating cerebral disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69928814D1 true DE69928814D1 (de) | 2006-01-12 |
| DE69928814T2 DE69928814T2 (de) | 2006-08-03 |
Family
ID=26149606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69928814T Expired - Fee Related DE69928814T2 (de) | 1998-09-03 | 1999-09-01 | Verwendung von TGF-Beta-Inhibitoren zum Behandeln von zerebralen Störungen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1109579B1 (de) |
| AT (1) | ATE311901T1 (de) |
| AU (1) | AU5857899A (de) |
| CA (1) | CA2342208A1 (de) |
| DE (1) | DE69928814T2 (de) |
| ES (1) | ES2252974T3 (de) |
| WO (1) | WO2000013705A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855690B2 (en) | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
| JP2003534385A (ja) * | 2000-06-01 | 2003-11-18 | チルドレンズ メディカル センター コーポレーション | 被験者の神経に有益な効果をもたらす方法および組成物 |
| US20030028905A1 (en) * | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61112018A (ja) * | 1984-11-06 | 1986-05-30 | Mitsubishi Chem Ind Ltd | 線溶増強剤 |
| AU3943793A (en) * | 1992-04-01 | 1993-11-08 | Whittier Institute For Diabetes And Endocrinology, The | Methods of inhibiting or enhancing scar formation in the CNS |
| US5399487A (en) * | 1993-03-04 | 1995-03-21 | Haematologic Technologies, Inc. | 6-peptidylamino-1-naphthalenesulfonamides useful as fluorogenic proteolytic enzyme substrates |
| CA2174098C (en) * | 1993-10-14 | 2011-01-25 | Douglas A. Melton | Method of inducing and maintaining neuronal cells |
-
1999
- 1999-09-01 ES ES99946087T patent/ES2252974T3/es not_active Expired - Lifetime
- 1999-09-01 WO PCT/EP1999/006433 patent/WO2000013705A1/en active IP Right Grant
- 1999-09-01 CA CA002342208A patent/CA2342208A1/en not_active Abandoned
- 1999-09-01 EP EP99946087A patent/EP1109579B1/de not_active Expired - Lifetime
- 1999-09-01 DE DE69928814T patent/DE69928814T2/de not_active Expired - Fee Related
- 1999-09-01 AU AU58578/99A patent/AU5857899A/en not_active Abandoned
- 1999-09-01 AT AT99946087T patent/ATE311901T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1109579B1 (de) | 2005-12-07 |
| EP1109579A1 (de) | 2001-06-27 |
| WO2000013705A1 (en) | 2000-03-16 |
| ES2252974T3 (es) | 2006-05-16 |
| ATE311901T1 (de) | 2005-12-15 |
| CA2342208A1 (en) | 2000-03-16 |
| DE69928814T2 (de) | 2006-08-03 |
| AU5857899A (en) | 2000-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE60023873D1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
| DE69906671D1 (de) | Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen | |
| WO2000061167A3 (en) | TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| ATE554169T1 (de) | Smad7-inhibitoren zur behandlung von krankheiten des zns | |
| ATE321548T1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
| ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
| ATE435026T1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| ATE334120T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| ATE266027T1 (de) | Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| DE50103012D1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWI |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |